Eleni C. Josephides

Guy's And St Thomas' NHS Foundation Trust
London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Independent Testing of Published CT Models for PD-L1 Status in Non-Small Cell Lung Cancer.

Independent Testing of Published CT Models for PD-L1 Status in Non-Small Cell Lung Cancer.

Journal: Radiology

Published: March 31, 2026

Resectability and Neoadjuvant Chemoimmunotherapy in Stage II-III Non-Small Cell Lung Cancer: A European Case-Vignette Survey.

Resectability and Neoadjuvant Chemoimmunotherapy in Stage II-III Non-Small Cell Lung Cancer: A European Case-Vignette Survey.

Journal: Interdisciplinary cardiovascular and thoracic surgery

Published: March 24, 2026

Guy's Cancer Cohort: Guy's Cancer Centre's Real-World Evidence Programme 5 years later.

Guy's Cancer Cohort: Guy's Cancer Centre's Real-World Evidence Programme 5 years later.

Journal: ESMO real world data and digital oncology

Published: February 06, 2026

Neoadjuvant chemoimmunotherapy in non-small cell lung cancer: evolving resectability criteria, biomarker-driven postoperative management, and emerging therapeutic strategies.

Neoadjuvant chemoimmunotherapy in non-small cell lung cancer: evolving resectability criteria, biomarker-driven postoperative management, and emerging therapeutic strategies.

Journal: Journal for immunotherapy of cancer

Published: January 17, 2026

Outcomes Following Radiotherapy for Oligoprogressive NSCLC on Immune Checkpoint Inhibitors: A Real-World, Multinational Experience.

Outcomes Following Radiotherapy for Oligoprogressive NSCLC on Immune Checkpoint Inhibitors: A Real-World, Multinational Experience.

Journal: Cancers

Published: November 28, 2025

Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity.

Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: August 17, 2025

Defining the Clinical Target Volume in Postoperative Thymic Epithelial Tumours - A Clinical Practice Guide for UK Clinical Oncologists.

Defining the Clinical Target Volume in Postoperative Thymic Epithelial Tumours - A Clinical Practice Guide for UK Clinical Oncologists.

Journal: Clinical oncology (Royal College of Radiologists (Great Britain))

Published: August 11, 2025

Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry.

Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry.

Journal: Journal for immunotherapy of cancer

Published: July 31, 2025

Predictors and Outcomes of Non-Small Cell Lung Carcinoma Patients Following Severe Immune Checkpoint Inhibitor Toxicity: A Real-World UK Multi-Centre Study.

Predictors and Outcomes of Non-Small Cell Lung Carcinoma Patients Following Severe Immune Checkpoint Inhibitor Toxicity: A Real-World UK Multi-Centre Study.

Journal: Cancers

Published: July 16, 2025

The utility of [18F]FDG PET in discriminating between local recurrence and inflammatory changes following SABR in primary lung cancer patients.

The utility of [18F]FDG PET in discriminating between local recurrence and inflammatory changes following SABR in primary lung cancer patients.

Journal: European journal of nuclear medicine and molecular imaging

Published: May 03, 2025

Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry.

Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry.

Journal: Journal for immunotherapy of cancer

Published: December 29, 2024

A Propensity-Matched Comparison Between Minimally Invasive Surgery and Stereotactic Radiotherapy in the Treatment of Clinical Stage IA Non-Small-Cell Lung Cancer (NSCLC).

A Propensity-Matched Comparison Between Minimally Invasive Surgery and Stereotactic Radiotherapy in the Treatment of Clinical Stage IA Non-Small-Cell Lung Cancer (NSCLC).

Journal: Clinical lung cancer

Published: December 09, 2024

Showing 1-12 of 22

Last Updated: 09/26/2026